Details of the Drug Reposition

General Information of This Drug (ID: DM3JDRP)

Drug Name
Cladribine   DM3JDRP
Synonyms
Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hairy cell leukaemia DISTD2E5 2A82.2 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple sclerosis DISB2WZI 8A40 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4799).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)